In what could become a textbook example of putting the cart alongside the horse, the FDA will ask its Arthritis Advisory Committee Monday to consider whether the data are sufficient to make axial spondyloarthritis (SpA), as defined by the Assessment of Spondyloarthritis International Society (ASAS) criteria, a new indication for arthritis drugs.